News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
517,569 Results
Type
Article (44220)
Company Profile (131)
Press Release (473218)
Section
Business (144703)
Career Advice (2381)
Deals (27878)
Drug Delivery (107)
Drug Development (67775)
Employer Resources (148)
FDA (15543)
Job Trends (11924)
News (263175)
Policy (29556)
Tag
Academia (2282)
Alliances (35720)
Alzheimer's disease (1282)
Approvals (15448)
Artificial intelligence (121)
Bankruptcy (300)
Best Places to Work (9109)
Biotechnology (82)
Breast cancer (112)
Cancer (1029)
Cardiovascular disease (96)
Career advice (1988)
Cell therapy (232)
Clinical research (53712)
Collaboration (337)
Compensation (200)
COVID-19 (2544)
C-suite (90)
Data (1031)
Diabetes (151)
Diagnostics (5087)
Drug pricing (97)
Earnings (57143)
Employer resources (136)
Events (74660)
Executive appointments (267)
FDA (16070)
Funding (285)
Gene therapy (185)
GLP-1 (644)
Government (3794)
Healthcare (14691)
Infectious disease (2630)
Inflammatory bowel disease (101)
Interviews (444)
IPO (13796)
Job creations (3152)
Job search strategy (1660)
Layoffs (450)
Legal (6902)
Lung cancer (166)
Manufacturing (169)
Medical device (11052)
Medtech (11055)
Mergers & acquisitions (14151)
Metabolic disorders (437)
Neuroscience (1553)
NextGen Class of 2024 (4969)
Non-profit (3157)
Northern California (1346)
Obesity (258)
Opinion (188)
Patents (101)
People (41805)
Phase I (16009)
Phase II (23254)
Phase III (19143)
Pipeline (456)
Policy (86)
Postmarket research (2196)
Preclinical (6487)
Radiopharmaceuticals (202)
Rare diseases (222)
Real estate (4247)
Regulatory (20205)
Research institute (2049)
Resumes & cover letters (400)
Southern California (1151)
Startups (2736)
United States (11726)
Vaccines (619)
Weight loss (213)
Date
Today (39)
Last 7 days (603)
Last 30 days (3341)
Last 365 days (31651)
2024 (29085)
2023 (34982)
2022 (45058)
2021 (48501)
2020 (45518)
2019 (36222)
2018 (27410)
2017 (27815)
2016 (25811)
2015 (27977)
2014 (21774)
2013 (17793)
2012 (18963)
2011 (19381)
2010 (17504)
Location
Africa (667)
Arizona (137)
Asia (30495)
Australia (5341)
California (2938)
Canada (960)
China (189)
Colorado (129)
Connecticut (149)
Europe (74031)
Florida (419)
Georgia (99)
Illinois (261)
Indiana (152)
Maryland (532)
Massachusetts (2307)
Michigan (119)
Minnesota (216)
New Jersey (852)
New York (830)
North Carolina (642)
Northern California (1346)
Ohio (110)
Pennsylvania (738)
South America (1031)
Southern California (1151)
Texas (398)
Washington State (324)
517,569 Results for "pharmamar s a".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Neurodegenerative disease
7 Alzheimer’s and Parkinson’s Programs Discarded in 2024
This year has seen several biopharma companies drop Alzheimer’s and Parkinson’s disease programs, but experts say plenty are still chasing these multi-billion-dollar markets.
November 4, 2024
·
6 min read
·
Heather McKenzie
Podcast
AbbVie’s Surprise Schizophrenia Flop, AstraZeneca’s China Drama, Hope in Huntington’s, More
A tale of two multi-billion schizophrenia deals, AstraZeneca touts strong sales while deflecting questions about an investigation into China exec, the Huntington’s pipeline builds momentum and layoffs continue with Sana Biotechnology and 23andMe.
November 13, 2024
·
1 min read
·
Heather McKenzie
GLP-1
Novo’s Semaglutide Linked to Reduced Alzheimer’s Risk in Real-World Study
Researchers have linked Novo Nordisk’s semaglutide to a 40% to 70% reduction in the risk of Alzheimer’s disease diagnosis in a study of medical records from 1 million patients.
October 24, 2024
·
2 min read
·
Annalee Armstrong
Huntington’s disease
Sage Scraps Huntington’s Hopeful After Disappointing Phase II Data
After previously failing studies in Parkinson’s and Alzheimer’s, dalzanemdor’s latest stumble in Huntington’s disease has pushed Sage Therapeutics to pull the plug on the NMDA receptor modulator.
November 20, 2024
·
2 min read
·
Tristan Manalac
Podcast
Lilly’s Q3 Miss, Novo’s MASH Win, CAR T’s Autoimmune Pivot, More
In our anniversary episode, we discuss a rare earnings miss for Eli Lilly, a pivotal metabolic dysfunction–associated steatohepatitis victory for Novo Nordisk’s Wegovy, growing excitement about CAR Ts for autoimmune disease and the ongoing controversy over HeLa cells.
November 6, 2024
·
1 min read
·
Heather McKenzie
Inflammatory bowel disease
Lilly’s Omvoh Beats J&J’s Stelara in Head-to-Head Phase III Crohn’s Disease Trial
At 52 weeks of follow-up, more patients on Eli Lilly’s monoclonal antibody Omvoh demonstrated histologic response, suggesting better long-term outcomes than Johnson & Johnson’s blockbuster therapy Stelara.
October 15, 2024
·
2 min read
·
Tristan Manalac
Huntington’s
5 Huntington’s Therapies to Watch
A fatal, highly hereditary illness with no disease-modifying treatments, Huntington’s is long overdue for a therapeutic win. Here,
BioSpace
looks at five candidates that could change the trajectory for patients.
November 11, 2024
·
5 min read
·
Kate Goodwin
Podcast
Trodelvy’s Bladder Cancer Withdrawal, Sage Therapeutics Layoffs, Sanofi’s Radiopharma Investment, More
Yet another therapy with FDA accelerated approval suffers a setback; Sage’s tough year continues; Sanofi drops $326 million in radiopharma while selling its consumer health unit; Novo Nordisk’s positive Rybelsus results in cardiovascular disease; and more.
October 23, 2024
·
1 min read
·
Heather McKenzie
GLP-1
Novo’s Wegovy Comparable to Madrigal’s Rezdiffra in Phase III MASH Trial: Analysts
In part 1 of the pivotal ESSENCE trial, Novo Nordisk’s weight loss drug Wegovy demonstrated “statistically significant and superior improvement” in liver fibrosis in patients with metabolic dysfunction–associated steatohepatitis.
November 1, 2024
·
3 min read
·
Heather McKenzie
Editorial
Why It’s OK to Talk About Catalent’s Pending Buyout by ‘Novo’
The group of like-named companies that include Novo Holdings and Novo Nordisk—the two tied to a multibillion-dollar buyout of Catalent currently under FTC review—ultimately send proceeds to the Novo Nordisk Foundation, one of the world’s largest charitable foundations.
October 24, 2024
·
6 min read
·
Jef Akst
1 of 51,757
Next
